2.929USD-2.70%Mkt Cap: 1.57B USDP/E: —Last update: 2026-05-26
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and eng…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap1.57B USD
Enterprise Value1.07B USD
Revenue (TTM)66.41M USD
Gross Profit3.30M USD
Net Income (TTM)-644.76M USD
Revenue/Share0.1390 USD
Last Price2.929 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees600
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.54
PEG—
EV/EBITDA-2.13
EV/Revenue16.05
P/S24.86
P/B1.61
EPS (TTM)-1.16
EPS (Forward)-0.88
52W Range
2.7704% of range7.180
52W High7.180 USD
52W Low2.770 USD
Profitability
Gross Margin4.45%
Oper. Margin-1985.55%
EBITDA Margin0.00%
Profit Margin-868.29%
ROE-57.01%
ROA-43.74%
Growth
Revenue Growth-56.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-371.81M USD
CapEx (TTM)8.63M USD
FCF Margin-267.73%
FCF Yield-11.30%
Net Debt-582.10M USD
Net Debt/EBITDA1.16
Balance Sheet
Debt/Equity0.07
Current Ratio5.47
Quick Ratio5.15
Book Value/Sh1.931 USD
Cash/Share1.235 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.5 (Hold)
Target (Mean)6.643 USD
Target Range3.000 USD – 10.00 USD
# Analysts7
Ownership
Shares Out.524.68M
Float512.96M
Insiders2.27%
Institutions68.61%
Short Interest
Short Ratio15.0d
Short % Float34.22%
Short % Out.32.28%
Shares Short171.32M
Short (prev mo.)173.93M
Technical
SMA 503.296 (-11.1%)
SMA 2004.328 (-32.3%)
Beta1.05
S&P 52W Chg28.31%
Avg Vol (30d)13.50M
Avg Vol (10d)14.98M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—